OncoMatch/Clinical Trials/NCT06995976
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
Is NCT06995976 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 68Ga-dPNE and 18F-FDG for malignant tumour.
Treatment: 68Ga-dPNE · 18F-FDG — As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.
Check if I qualifyEligibility summary
For patients with Malignant Tumor.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify